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present in 2/6 FLU/BU and 4/9 FLU/MEL evaluable patients. Six
of 12 patients in the FLU/BU died of relapse (n4) and/or infec-
tion (n2, 1 within d100 ) and 3 of 10 patients in the FLU/MEL
died of relapse. In conclusion, since in allogeneic PBSC transplan-
tation the FLU/BU regimen seems to have a myelotoxicity com-
parable to FLU/MEL, it could be used in allotransplant for elderly
patients and may represent a platform for donor lymphocyte infu-
sions in high risk patients.
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ALEMTUZUMAB IMMUNOTHERAPY PROVIDES EFFECTIVE CYTORE-
DUCTION PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION FOR
REFRACTORY LYMPHOPROLIFERATIVE DISORDERS
Voralia, M.1,2; Hasegawa, W.1,2; McAllister, R.2; Evjen, A.2; Briggs,
S.2; Doell, H.2; Danyluk, P.2 1. University of Saskatchewan, Saskatoon,
SK, Canada; 2. Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Introduction: The optimal cytoreductive therapy for refractory
chronic lymphoproliferative disorders prior to allogeneic stem cell
transplantation is not well deﬁned. Immunotherapy may represent
an alternative cytoreductive strategy in chemotherapy refractory
disease. We assessed the role of alemtuzumab (anti-CD52, CAM-
PATH) immunotherapy in reducing disease bulk pretransplant in
a pilot single center clinical protocol. Patients and Methods:
Patients with CLL and lymphoplasmacytic lymphoma (LPL) re-
fractory to at least two prior lines of chemotherapy, age less than 65
years, and adequate organ function received alemtuzumab mono-
therapy 30 mg. intravenously thrice weekly for 8–12 weeks. Mo-
lecular, hematologic, and radiological responses were measured.
Transplantation conditioning consisted of Fludarabine/Melphalan
or BEAM. Results: Between 10/2002 and 10/2004, 7 patients (6
refractory CLL, 1 refractory LPL) received alemtuzumab cytore-
duction and allogeneic stem cell transplantation. All patients had
received prior ﬂudarabine or alkylator therapy; 1 had received
rituximab. High-risk cytogenetic markers (p53 or Rb1 deletions)
were present in 4 of 6 CLL patients, as assessed by FISH. Marrow
involvement decreased from a mean of 80% pre-alemtuzumab to
15% post; 3 patients attained complete marrow clearance. Hema-
tologic remission following alemtuzumab was achieved in 4 of 6
CLL patients. Partial (3/7) or complete (4/7) molecular remission
was achieved in all patients after immunotherapy. Four patients
exhibited partial radiologic responses; 3 were unchanged. Adverse
effects were rare (CMV viremia in 2 patients; moderate cytopenias
requiring brief therapy interruption in 4). All 7 patients proceeded
to allogeneic stem cell transplantation (4 MRD, 3 MUD), one in
clinical relapse. Neutrophil engraftment was rapid (less than 20
days); one patient had delayed platelet engraftment. Although early
to assess long-term disease response, 4/4 evaluable patients have
achieved a complete molecular, hematologic, and radiologic re-
sponse at 6 months post-transplant; one patient remains in com-
plete remission at 2 years. One patient died of sepsis at 3 months.
Conclusion: Alemtuzumab immunotherapy is an effective cytore-
ductive regimen for chemotherapy-refractory lymphoproliferative
disorders prior to allogeneic stem cell transplantation, and bears
testing in a larger multi-centre Phase II/III protocol.
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THE FREQUENCY OF EARLY COMPLICATIONS AFTER ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH MYELOA-
BLATIVE (MA) AND NON-MYELOABLATIVE (NMA) CONDITIONING
REGIMEN
Golovchenko, R.A.; Moiseev, S.I. The Russian Institute of Hematology
and Transfusiology, St-Petersburg, Russian Federation.
The frequency of early complications (before 100 days) of HSCT
was measured on 38 patients (pts) with hemoblastosis, underwent
allogeneic HSCT (allo HSCT) from HLA-matched related donors
(median age 24.4 	 1.8). Conditioning regimens were myeloabla-
tive in 28 patients (73.7%, median age 21 	 2.0) and consist
BuCy, and NMA in 10 patients (26.3%, median age 29.9 	 3.6),
consist of FluBuALG or FluBuAlkeran. In group of MA
HSCT 13 patients had CML, 9 - ALL, 5 - AML and 1 - MDS. In
group of NMA HSCT 6 patients had CML, 2 - ALL, 1 - AML, 1
- MDS. The frequency of bacterial infectious complications in
NMA HSCT group was 21.4% and in MA HSCT group 20%
(p0.05). The frequency of febrile neutropenia was signiﬁcantly
lower in NMA HSCT group: 30% and 67,8% respectively
(p
0.05). Viral complications was observed in 14 (50%) patients in
group of MA HSCT and in 5 patients (50%) in NMA group. 8 pts
(28.6%) in MA group developed CMV viremia and 4 pts (40%) in
NMA group (p0.05). Herpes simplex infection was diagnosed in
6 pts (21.4%) in group of MA HSCT and in 1 pt (10%) in NMA
HSCT group (p0.05). Hemorrhagic complications were ob-
served in 14 patients with MA HSCT (50%) and in 4 (40%) with
NMA HSCT (p0.05). Acute graft versus host disease (GVHD)
grade 2–4 was observed in 5 patients with MA HSCT (17.8%) and
in 1 pt (10%) in group of NMA HSCT (p0.05) and chronic
GVHD was developed in 9 pts in MA HSCT group and in 1 pt in
NMA HSCT group (p0.05). The toxicity of conditioning regi-
mens (only grade 3–4 were considered) for cardiovascular system
was signiﬁcant lower for NMA HSCT group: 1 pt (10%) and 11
pts (39.2%), (p
0.05). The toxicity for digestive system was lower
in NMA HSCT group too: 5 pts (50%) and 28 (100%) respectively
(p
0.05). The for respiratory system (7.1% and 0% respectively,
p0.05), urogenital system (25% and 20% respectively, p0.05),
and hepar (46.3% and 40% respectively, p0.05) had no signiﬁ-
cant differences between two groups. 1 pt in group NMA HSCT
had veno-occlusive disease (10%) and no cases in group MA
HSCT (p0.05). The engraftment of stem cells was achieved in
100% cases as in MA as NMA HSCT groups (25.5 	 4.5 and
20.5 	 1.2 days respectively, p0.05). We conclude, that there are
no differences between patients groups with MA and NMA HSCT
in spite of engraftment kinetics, the frequency of infectious com-
plications, the frequency of acute and chronic GVHD. But the use
of NMA HSCT accompany note lower toxicity on cardiovascular
and digestive systems.
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UNRELATED CORD BLOOD TRANSPLANTATION WITH MYELOABLATIVE
CONDITIONING FOR ADULT PATIENTS WITH HEMATOLOGICAL MALIG-
NANCIES
Yamane, A.; Mori, T.; Aisa, Y.; Nakazato, T.; Yamazaki, R.; Ikeda, Y.;
Okamoto, S. Division of Hematology, Keio University School of Medi-
cine, Tokyo, Japan.
Background: Umbilical cord blood (CB) has been rapidly estab-
lished as an alternative source of stem cells to bone marrow or
peripheral blood for unrelated allogeneic hematopoietic stem cell
transplantation. However, concern about the engraftment failure
probably due to low number of stem cells has limited its use
particularly for adult patients. We report the results of unrelated
cord blood transplantation (CBT) for 8 adult patients with hema-
tological malignancies. Patients and Methods: Patients with he-
matological malignancies without a suitable related donor were
eligible. Conditioning consisted of total body irradiation (TBI; 120
cGy) followed by high-dose cytarabine (3 g/m2  8) for myeloid
malignancies, and TBI (120 cGy) followed by high-dose cytarabine
(2 g/m2  4) and cyclophosphamide (60 mg/kg  2) for lymphoid
malignancies. For acute graft-versus-host disease prophylaxis, ta-
crolimus (0.03 mg/kg) and short-term methotrexate (15 mg/m2on
day 1, 10 mg/m2on days 3, 6) were given. All patients received
G-CSF infusion starting on day 1 until neutrophil recovery was
obtained. Cord blood unit was selected according to the nucleated
cell number (more than 2.0  107/kg) and HLA compatibility (less
than serological 2-loci mismatches). Results: Eight patients were
enrolled. Median age was 39 years (range, 20–58), and median
number of cryopreserved nucleated cells in the CB unit was 2.9 
107/kg (range, 2.0–4.7  107/kg). Their diagnoses were AML in 3
(2nd CR, 2; primary induction failure (PIF), 1), Ph1 ALL (1st
CR) in 2, advanced MDS in 2, and CML (2nd CP) in 1. All patients
achieved engraftment with full donor chimerism. Acute GVHD
occurred in 5 patients, and the grading was grade I in 2 and grade
II in 3 patients. Chronic GVHD occurred only in 2 patients. No
transplant-related mortality was observed, and overall survival was
100% with a median follow-up 14.7 months (range, 6.1–33.8
months). One patient with AML (PIF) relapsed 13 months after
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